Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 117 for “"GLP-1"”.
-
Studies of the Physical Stability of GLP-1 & Chemically Modified Forms of GLP-1
… amyloid fibrillation of the therapeutic peptide GLP-1 and chemically modified forms of GLP-1. GLP-1, a metabolic hormone, has the ability to decrease blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin. Previous measurements of GLP-1 aggregation revealed that, …
-
Αγωνιστές των υποδοχέων GLP-1: Ασφάλεια και οργανοπροστασία
Το πεπτίδιο τύπου γλυκαγόνης‑1 (GLP‑1) αποτελεί μια ινκρετίνη με κεντρικό ρόλο στη ρύθμιση του μεταβολισμού και της ενεργειακής ομοιόστασης. Δεσμεύεται σε εξειδικευμένους υποδοχείς GLP‑1 που εντοπίζονται σε διάφορους ιστούς του ανθρώπινου οργανισμού και είναι ευρέως γνωστό για τη συμβολή του στον …
-
The Cardiovascular Effect of GLP-1 in Humans
The incretin glucagon-like peptide-1 (GLP-1) abolishes post-ischemic left ventricular contractility (stunning) in humans but the mechanism remains elusive. I hypothesized that this effect is mediated by peripheral or coronary vasodilatation. A comprehensive assessment of the haemodynamic effects of …
-
Glp-1 αγωνιστές και γαστρική κένωση: Μία συστηματική ανασκόπηση
… Παρά τα οφέλη τους σε πολλαπλά όργανα, τα GLP1 ανάλογα έχουν συσχετιστεί με καθυστέρηση της κένωσης του στομάχου, αυξάνοντας λοιπόν τον κίνδυνο εισρόφησης κατά την εισαγωγή στην αναισθησία. Από τα φάρμακα της κατηγορίας αυτής, διακρίνεται η σεμαγλουτίδη λόγω των ιδιαιτεροτήτων και της …
-
Characterisation and pharmacological regulation of GLP-1-mediated glucose homeostasis
… glucose homeostasis. Glucagon-like peptide 1 (GLP-1), which is an incretin hormone, activates the predominantly Gαs-coupled glucagon-like peptide 1 receptor (GLP-1R), which is a class B G protein-coupled receptor (GPCR), to mediate glucose homeostasis. It does so by promoting glucose stimulated …
-
Cardioprotective effects of Glucagon-like Peptide 1 (GLP-1) and their mechanisms
$\textbf{Background}$ Glucagon-like Peptide 1 (GLP-1) is a human incretin hormone that has been demonstrated to protect against non-lethal ischaemia reperfusion injury in the left ventricle in humans. It has been suggested from some animal research that this protection may be mediated through the …
-
Cardiovascular Effects of GLP-1 and Glucagon Dual Receptor Agonism in Humans
… IV inhibitors, glucagon like peptide-1 (GLP-1) receptor agonists and selective sodium-glucose transporter-2 inhibitors (SGLT2i). These medications have transformed treatment pathways and prognosis for individuals with T2DM as well as obesity (GLP-1 receptor agonists), heart failure …
-
Studies on the physical stability of a C-terminally amidated variant of GLP-1
… peptide therapeutic, glucagon-like peptide 1 (GLP-1). This peptide is responsible for many regulatory mechanisms affecting the level of glucose in the bloodstream. Unfortunately, it was shown that GLP-1 has a great propensity to aggregate over a wide pH range that inhibits its function. The …
-
Central mechanisms underlying the synergistic anorectic effect of CCK and GLP-1 combination therapy
… (CCK) and Glucagon-like peptide-1 (GLP-1) are gut hormones produced in response to meal ingestion that promote satiety and meal termination. Co-infusion of long-acting CCK and GLP-1 receptor agonists have been shown to synergistically reduce food intake and body-weight in …
-
SDOH, GLP-1 Prescription Patterns and MASLD-associated Liver Disease in a Real World Population
… examine predictors of advanced liver disease and GLP-1 RA receptor agonist use among a cross-sectional study of adults with metabolic dysfunction–associated steatotic liver disease (MASLD) and related conditions. Variables included diagnoses, prescriptions, demographics, BMI, diabetes, insurance, …
-
Targeting macrophages GLP-1 receptor pathways as emerging therapies to ameliorate cardiac remodelling associated with diabetes
… disease in diabetes. Glucagon-like peptide (GLP-1) is an incretin hormone, which confers proven glycaemic control in diabetes, and also demonstrates cardioprotective effects. Indeed, we have recently reported that the GLP-1 analogue, exendin-4, promotes specific benefits on cardiac …
-
Beyond cravings: A phenomenological exploration of relief among individuals with substance use disorders on GLP-1 medications
Submission original under an indefinite embargo labeled 'Open Access'. The submission was exported from vireo on 2025-10-19 without embargo terms
-
Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients
… of glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promise in reducing cardiovascular events and improving kidney function in patients with type 2 diabetes. Due to these hopeful improvements, kidney transplant recipients (KTRs) have started using GLP-1RA. However, their effects …
-
Παγκρεατικές και ηπατικές επιδράσεις των GLP-1 αναλόγων και αγωνιστών υποδοχέων: βιβλιογραφική ανασκόπηση της ασφάλειας και των πιθανών μηχανισμών
… Στο πλαίσιο αυτό οι αγωνιστές του υποδοχέα GLP-1 έχουν αναδειχθεί ως μια ιδιαίτερα σημαντική κατηγορία φαρμάκων. Το γαστρεντερικό GLP-1 συμμετέχει φυσιολογικά στη ρύθμιση της γλυκόζης μέσω ενίσχυσης της γλυκοζοεξαρτώμενης έκκρισης ινσουλίνης, καταστολής της έκκρισης γλυκαγόνης, επιβράδυνσης …
-
Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model
… some flavanols increase glucagon-like peptide 1 (GLP- 1) levels. GLP-1 is a feeding hormone that increases insulin secretion after carbohydrate consumption and increased GLP-1 levels may be responsible for some of the beneficial effects on glycemic control after flavanol consumption. The present …
-
Novel Roles of GLP-1 and GLP-2 in the Regulation of Hepatic Lipid/Lipoprotein Homeostasis and the Involvement of BAT Activation
… The gut derived hormones glucagon-like peptide (GLP)-1 and GLP-2 have been shown to signal through neuronal pathways and display postprandial hypolipidemic and hyperlipidemic actions respectively. Furthermore, activation of brown adipose tissue (BAT) through the sympathetic nervous system also …
-
Understanding Patient Perceptions and Behavioral Intentions Toward GLP-1 Receptor Agonists for Weight Management in the United States: A Health Belief Model Approach
… Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management in the United States; however, limited evidence exists regarding the perceptual and behavioral factors influencing medication adherence among adult users. Prior research has largely focused on …
Page 1 of 6